Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system

被引：2

作者：

Auernhammer, Christoph Josef ^{[1
,5
]}

Spitzweg, Christine ^{[1
,5
]}

Boeck, Stefan ^{[2
,5
]}

Knoesel, Thomas ^{[3
,5
]}

Bartenstein, Peter ^{[4
,5
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany

[3] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany

[4] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Klin & Poliklin Nuklearmed, Munich, Germany

[5] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Interdisziplinares Zentrum Neuroendokrine Tumoren, Campus Grosshadern, Munich, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2019年 / 144卷 / 20期

关键词：

neuroendocrine tumors; biotherapy; peptid receptor radionuclide therapy (PRRT); chemotherapy; molecular targeted therapy;

D O I：

10.1055/a-0801-3686

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Current guidelines have been published for the diagnosis and therapy of neuroendocrine neoplasms of the gastroenteropancreatic (GEP) system 1 . Systemic therapy of inoperable advanced neuroendocrine tumors includes biotherapy with somatostatin analogas, peptid receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-TATE, chemotherapy with steptozotocin/5-fluorouracil or capecitabine/temozolomide and molecular targeted therapy with everolimus or sunitinib 1 2 . For symptom control in patients with carcinoid syndrome biotherapy with somatostatin analogs, PRRT, loco-regional and local-ablative interventional procedures of liver metastases as well as the peripheral serotonin synthesis inhibitor telotristat Ethyl 1 2 3 4 are highly effective. Novel aspects and developments in the diagnosis and treatment of neuroendocrine tumors will be discussed in this review.

引用

页码：1390 / 1395

页数：6

共 21 条

[1] Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies [J].

Auernhammer, Christoph J. ;

Spitzweg, Christine ;

Angele, Martin K. ;

Boeck, Stefan ;

Grossman, Ashley ;

Nolting, Svenja ;

Ilhan, Harun ;

Knosel, Thomas ;

Mayerle, Julia ;

Reincke, Martin ;

Bartenstein, Peter .

LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05) :404-415

[2]

Capdevila Castillon J, 2018, ANN ONCOL S8, V29, pAbstract 13070, DOI [10.1093/annonc/mdy293, DOI 10.1093/ANNONC/MDY29]

[3] Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). [J].

Chan, Jennifer A. ;

Faris, Jason Edward ;

Murphy, Janet E. ;

Blaszkowsky, Lawrence Scott ;

Kwak, Eunice Lee ;

McCleary, Nadine Jackson ;

Fuchs, Charles S. ;

Meyerhardt, Jeffrey A. ;

Ng, Kimmie ;

Zhu, Andrew X. ;

Abrams, Thomas Adam ;

Wolpin, Brian M. ;

Zhang, Sui ;

Reardon, Amanda ;

Fitzpatrick, Bridget ;

Kulke, Matthew H. ;

Ryan, David P. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

[4] The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications [J].

Cives, Mauro ;

Pelle', Eleonora ;

Quaresmini, Davide ;

Rizzo, Francesca Maria ;

Tucci, Marco ;

Silvestris, Franco .

NEUROENDOCRINOLOGY, 2019, 109 (02) :83-99

[5] Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses [J].

de Mestier, Louis ;

Walter, Thomas ;

Brixi, Hedia ;

Evrard, Camille ;

Legoux, Jean-Louis ;

de Boissieu, Paul ;

Hentic, Olivia ;

Cros, Jerome ;

Hammel, Pascal ;

Tougeron, David ;

Lombard-Bohas, Catherine ;

Rebours, Vinciane ;

Ruszniewski, Philippe ;

Cadiot, Guillaume .

NEUROENDOCRINOLOGY, 2019, 108 (04) :343-353

[6] Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms [J].

de Mestier, Louis ;

Cros, Jerome ;

Neuzillet, Cindy ;

Hentic, Olivia ;

Egal, Axel ;

Muller, Nelly ;

Bouche, Olivier ;

Cadiot, Guillaume ;

Ruszniewski, Philippe ;

Couvelard, Anne ;

Hammel, Pascal .

NEUROENDOCRINOLOGY, 2017, 105 (04) :412-425

[7] Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms [J].

Grillo, Federica ;

Florio, Tullio ;

Ferrau, Francesco ;

Kara, Elda ;

Fanciulli, Giuseppe ;

Faggiano, Antongiulio ;

Colao, Annamaria .

[8] Management of carcinoid syndrome: a systematic review and meta-analysis [J].

Hofland, Johannes ;

Herrera-Martinez, Aura D. ;

Zandee, Wouter T. ;

de Herder, Wouter W. .

[9] Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro [J].

Jin, Xi-Feng ;

Auernhammer, Christoph J. ;

Ilhan, Harun ;

Lindner, Simon ;

Nolting, Svenja ;

Maurer, Julian ;

Spottl, Gerald ;

Orth, Michael .

JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (09) :1240-1246

[10] Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important [J].

Jin, Xi-Feng ;

Spampatti, Matilde P. ;

Spitzweg, Christine ;

Auernhammer, Christoph J. .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2018, 19 (02) :145-158

← 1 2 3 →